SCHAUMBURG, Ill. — Natus Sensory has acquired TheraB Medical, adding wearable phototherapy technology to its newborn care portfolio as the company looks to broaden treatment options for neonatal jaundice across a range of care settings.
TheraB Medical develops phototherapy solutions designed to treat neonatal jaundice while supporting family-centered care. The acquisition brings Natus Sensory its first FDA-cleared wearable phototherapy system, a swaddle-style garment intended to deliver effective treatment while allowing infants to remain close to caregivers.
Company officials said the deal strengthens Natus Sensory’s position in newborn care by complementing its existing hospital-based solutions with more flexible treatment options that can be used in additional clinical environments.
“At Natus Sensory, our vision in newborn care is simple and deeply personal: to help give every single baby the best possible start in life,” said Peter Reimer, chief executive officer of Natus Sensory. “TheraB Medical’s wearable phototherapy innovation aligns strongly with that vision. It complements our existing hospital-based solutions while expanding how and where effective care can be delivered, always grounded in real clinical needs and focused on improving outcomes for newborns and their families.”
TheraB Medical’s lead product, SnugLit, received FDA 510(k) clearance in January 2026. The device is designed as a wearable, swaddle-style phototherapy system that treats neonatal jaundice while supporting bonding and family-integrated care models that are increasingly being adopted by hospitals worldwide.
Natus Sensory said adding wearable phototherapy expands the range of options available to clinicians, allowing treatment to be tailored to the needs of individual patients while maintaining effective clinical outcomes.
“This acquisition validates TheraB’s mission to improve outcomes for infants diagnosed with neonatal jaundice, and Natus Sensory’s global presence in the pediatric community will enable broader access to SnugLit’s innovative approach to phototherapy across hospitals and clinical settings,” said Chris Mathia, chief executive officer of TheraB Medical.
Alexa Jones, founder of TheraB Medical and inventor of SnugLit, said joining Natus Sensory will accelerate adoption of the technology. “TheraB was founded to advance effective jaundice treatment, and SnugLit was developed to preserve the critical bond between mother and baby. Joining Natus Sensory accelerates our path forward, expanding future access for clinicians, hospitals, and families who need it most.”
Natus Sensory said the acquisition reflects its continued investment in innovation within newborn care, as healthcare providers increasingly seek technologies that support evolving care models while maintaining clinical reliability and effectiveness.
